Dr Reddy’s Pressing On In Russia, China Approvals Add Spark
Sputnik Light Being Pursued As Universal Booster
Momentum for Dr Reddy’s in China as a string of approvals including for lenalidomide come through, while it appears to be on an even keel in Russia, a market where several foreign firms have cutback activities in the wake of the Ukraine conflict. Will the Indian firm’s Russia strategy payback?
You may also be interested in...
The sharp escalation in prices of raw materials, solvents, excipients and logistics in a volatile operating environment charged by geopolitical tensions and supply chain challenges was one of the key talking points at the fiscal fourth quarter earnings discussions of leading Indian firms. With little hope for respite any time soon, companies are devising strategies to cope.
Many health care businesses have condemned the war in Ukraine while prioritizing the safety of local employees and pledging support and humanitarian aid. They must also consider their own operational issues during and after the conflict.
Leading Indian firms with operations in the war zone stare at uncertainties and disruptions as sanctions by the US and Western allies threaten to choke the Russian economy.